The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
Tauopathies: new perspectives and challenges
Y Zhang, KM Wu, L Yang, Q Dong, JT Yu - Molecular neurodegeneration, 2022 - Springer
Background Tauopathies are a class of neurodegenerative disorders characterized by
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …
neuronal and/or glial tau-positive inclusions. Main body Clinically, tauopathies can present …
Blood‐based biomarkers for Alzheimer's disease
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
Dissecting the clinical heterogeneity of early-onset Alzheimer's disease
Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear …
Objectives This longitudinal study compared emerging plasma biomarkers for
neurodegenerative disease between controls, patients with Alzheimer's disease (AD), Lewy …
neurodegenerative disease between controls, patients with Alzheimer's disease (AD), Lewy …
Expectations and clinical meaningfulness of randomized controlled trials
RC Petersen, PS Aisen, JS Andrews… - Alzheimer's & …, 2023 - Wiley Online Library
Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a
therapeutic intervention, and there has been considerable discussion on what constitutes a …
therapeutic intervention, and there has been considerable discussion on what constitutes a …
Plasma biomarkers predict Alzheimer's disease before clinical onset in Chinese cohorts
H Cai, Y Pang, X Fu, Z Ren, L Jia - Nature Communications, 2023 - nature.com
Plasma amyloid-β (Aβ) 42, phosphorylated tau (p-tau) 181, and neurofilament light chain
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …
(NfL) are promising biomarkers of Alzheimer's disease (AD). However, whether these …
Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Y Qiao, Y Chi, Q Zhang, Y Ma - Frontiers in aging neuroscience, 2023 - frontiersin.org
Objective We performed a systematic review and meta-analysis of the cognitive
effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD). Methods …
effectiveness and safety of lecanemab on subjects with Alzheimer's disease (AD). Methods …
Validity and performance of blood biomarkers for Alzheimer disease to predict dementia risk in a large clinic-based cohort
Background and Objective Blood biomarkers for Alzheimer disease (AD) have consistently
proven to be associated with CSF or PET biomarkers and effectively discriminate AD from …
proven to be associated with CSF or PET biomarkers and effectively discriminate AD from …
The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease
Over the past several years, there has been a surge in blood biomarker studies examining
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …
the value of plasma or serum neurofilament light (NfL) as a biomarker of neurodegeneration …